drugset / Trial / NCT01085812
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
Timeline
- Start
- 2010-03
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levomilnacipran | Small molecule | 40 mg | Oral |
| Subject | Levomilnacipran | Small molecule | 80 mg | Oral |
| Subject | Levomilnacipran | Small molecule | 120 mg | Oral |